Deneus schreef op 23 augustus 2018 23:49:
The U.S. Food and Drug Administration approved Takhzyro (lanadelumab), the first monoclonal antibody approved in the U.S. to treat patients 12 years and older with types I and II hereditary angioedema (HAE). HAE is a rare and serious genetic disease that affects people with low levels of and poorly functioning C1-INH proteins in the body. This results in recurrent, unpredictable episodes of severe swelling in different areas of the body, including the stomach, limbs, face and throat.
The most common adverse drug reactions in patients taking Takhzyro in clinical trials are injection site reactions, upper respiratory infections, headache, rash, muscle pain, dizziness and diarrhea.
For more information, please visit: Takhzyro.
This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at
druginfo@fda.hhs.gov.
For additional drug information, please visit the DDI Web page.
For up-to-date drug information, follow the FDA’s Division of Drug Information on Twitter: FDA_Drug_Info.
This service is provided to you at no charge by the U.S. Food & Drug Administration (FDA).